Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients

ICI therapy has greatly improved patient outcomes in melanoma, but at the cost of immune-related adverse events (irAEs). Data on the chronicity of irAEs, especially in real-world settings, are currently limited. We performed a retrospective chart review of 161 adult patients with melanoma treated wi...

Full description

Bibliographic Details
Main Authors: Justin Tong, Adi Kartolo, Cynthia Yeung, Wilma Hopman, Tara Baetz
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Current Oncology
Subjects:
oncology
immune checkpoint inhibitor
immunotherapy
melanoma
Online Access:https://www.mdpi.com/1718-7729/29/10/629

Similar Items

Similar Items